Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-671 in gout
NCT05818085Phase 3Completed
- Sponsor
- Atom Therapeutics
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of lingdolinurad in gout (3 arms), sponsored by Atom Therapeutics. Primary endpoint: Proportion of participants who achieve serum uric acid levels <6.0 mg/dL (<0.360 mmol/L) at 28 weeks. Started Aug 2023; status: completed.
02
Drugs
lingdolinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT05818085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818085.